Biomind Labs Company Top Insiders
| BMNDF Stock | USD 0.11 0.00 0.00% |
Biomind Labs employs about 9 people. The company is managed by 7 executives with a total tenure of roughly 21 years, averaging almost 3.0 years of service per executive, having 1.29 employees per reported executive. Examination of Biomind Labs' management performance can provide insight into the company performance.
| Alejandro Antalich Insider CEO Director |
| Oscar Leon Insider CFO Director |
Biomind |
Biomind Labs Management Team Effectiveness
The company has return on total asset (ROA) of (2.5883) % which means that it has lost $2.5883 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.7242) %, meaning that it generated substantial loss on money invested by shareholders. Biomind Labs' management efficiency ratios could be used to measure how well Biomind Labs manages its routine affairs as well as how well it operates its assets and liabilities.Biomind Labs holds a total of 74.76 Million outstanding shares. Biomind Labs shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 90.07 percent of Biomind Labs outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Biomind Labs in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Biomind Labs, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Biomind Labs Workforce Comparison
Biomind Labs is rated fourth in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 1,393. Biomind Labs maintains roughly 9.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.
Biomind Labs Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Biomind Labs Price Series Summation is a cross summation of Biomind Labs price series and its benchmark/peer.
Biomind Labs Notable Stakeholders
A Biomind Labs stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biomind Labs often face trade-offs trying to please all of them. Biomind Labs' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biomind Labs' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Alejandro Antalich | CEO Director | Profile | |
| Oscar Leon | CFO Director | Profile | |
| Juan Presa | Chief Officer | Profile | |
| Paola Dellavalle | Chief Officer | Profile | |
| Marcelo Falchi | Head Unit | Profile | |
| Magdalena MA | Head Communication | Profile | |
| Martin Daners | Head Affairs | Profile |
About Biomind Labs Management Performance
The success or failure of an entity such as Biomind Labs often depends on how effective the management is. Biomind Labs management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biomind management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biomind management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. Biomind Labs is traded on OTC Exchange in the United States.
Biomind Labs Workforce Analysis
Traditionally, organizations such as Biomind Labs use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biomind Labs within its industry.Biomind Labs Manpower Efficiency
Return on Biomind Labs Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 481.4K | |
| Net Loss Per Executive | 618.9K |
Complementary Tools for Biomind Pink Sheet analysis
When running Biomind Labs' price analysis, check to measure Biomind Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomind Labs is operating at the current time. Most of Biomind Labs' value examination focuses on studying past and present price action to predict the probability of Biomind Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomind Labs' price. Additionally, you may evaluate how the addition of Biomind Labs to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |